Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Axsome Therapeutics, Inc. - Common Stock (NQ:AXSM)

108.30 +0.77 (+0.72%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Axsome Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Why Axsome Therapeutics Stock Is Sinking Today
A short-seller report is causing a sell-off of the biotech stock. 
Via The Motley Fool
15 Analysts Assess Axsome Therapeutics: What You Need To Know
Via Benzinga
Hello Group And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
3 Monster Stocks in the Making You Can Buy Right Now
These stocks might not be small for too much longer. 
Via The Motley Fool
The 3 Most Undervalued Biotech Stocks to Buy in May 2024
Three most undervalued biotech stocks to buy now will take off in the coming years and bring back continuous, hefty returns. 
Via InvestorPlace
Prediction: These 2 Growth Stocks Could Triple By 2030
These companies have a habit of silencing the bears. 
Via The Motley Fool
Peeling Back The Layers: Exploring Axsome Therapeutics Through Analyst Insights
Via Benzinga
Analyst Ratings For Axsome Therapeutics
Via Benzinga
2 Under-the-Radar Growth Stocks to Consider
Don't ignore these innovative companies. 
Via The Motley Fool
Axsome Therapeutics (AXSM) Q1 2024 Earnings Call Transcript
AXSM earnings call for the period ending March 31, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
AXSM Stock Earnings: Axsome Therapeutics Beats EPS, Beats Revenue for Q1 2024
AXSM stock results show that Axsome Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
3 Biotech Stocks with Blockbuster Drug Pipelines: April Edition
Here are our top three choices for biotech stocks with blockbuster drug pipelines that could pay off massively in the future. 
Via InvestorPlace
Billionaires Are Buying These 2 Ultra-High Yield Dividend Stocks Hand Over Fist. Are They Smart Buys for Your Portfolio?
Stocks that work for billionaires aren't necessarily appropriate for every investor. 
Via The Motley Fool
3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch List
Don’t miss out on these three strong buy biotech stocks that are leaders to add to your portfolio for Q2 this year. 
Via InvestorPlace
What Analysts Are Saying About Axsome Therapeutics Stock
Via Benzinga
What Analysts Are Saying About Axsome Therapeutics Stock
Via Benzinga
Earnings Outlook For Axsome Therapeutics
Via Benzinga
The Latest Analyst Ratings For Axsome Therapeutics
Via Benzinga
Tesla To $120? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
What's Going On Neurology-Focused Axsome Therapeutics' Stock On Monday?
Unlock insights from the SYMPHONY Phase 3 trial of AXS-12 (reboxetine) in narcolepsy patients. AXS-12 demonstrated significant reductions in cataplexy attacks, improved daytime wakefulness, and... 
Via Benzinga
Buying These Dirt-Cheap Stocks Could Be a Brilliant Move
The price could be right for these three biopharma stocks. 
Via The Motley Fool
3 Under-the-Radar Biotech Stocks With Upcoming Catalysts in 2024
Find out which under-the-radar biotech stocks have major catalysts on the horizon, and unlock their explosive growth potential. 
Via InvestorPlace
3 Biotech Stocks to Buy and Hold for the Next 10 Years
There's a lot to like about these three drugmakers right now, and that shouldn't stop anytime soon. 
Via The Motley Fool
Axsome Therapeutics (AXSM) Q4 2023 Earnings Call Transcript
AXSM earnings call for the period ending December 31, 2023. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Neurology-Focused Axsome Therapeutics Reports Deeper Than Expected Q4 Loss, Updates Upcoming Pipeline Milestones
Axsome Therapeutics Q4 2023 revenues surge to $71.53 million, Auvelity sales hit $130.1 million for the year. Sunosi sees 67% YoY growth. 
Via Benzinga
Axsome Tumbles On An Unexpected Setback For Its Alzheimer's Drug
The company is testing a treatment for patients with agitation due to Alzheimer's disease. 
Via Investor's Business Daily
2 Stocks That Could Double Your Money in 5 Years
These market-beating stocks could be just getting started. 
Via The Motley Fool
UBS Bullish On This Depression Drug Maker, Says Alzheimer's Agitation Data Is Attractive Catalyst
UBS bullish on Axsome's Auvelity launch and pipeline, foreseeing $1 billion sales by 2030. Buy rating, $111 price target. Positive Phase 3 data for Alzheimer's Agitation and Narcolepsy. 
Via Benzinga
Cramer Praises Asset Manager's 'Amazing Quarter,' But As For SolarEdge? 'Too Hard To Own'
On CNBC’s "Mad Money Lightning Round," Jim Cramer recommended buying BlackRock, Inc. (NYSE: BLK). 
Via Benzinga
Earnings Scheduled For February 20, 2024
Companies Reporting Before The Bell • Barclays (NYSE:BCS) is likely to report quarterly earnings at $0.36 per share on revenue of $7.38 billion. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback